KD–Mineral and Bone Disorder (CKD-MBD) is a systemic complication of chronic kidney disease involving disturbances in calcium, phosphorus, vitamin D, and parathyroid hormone metabolism. If untreated, it leads to bone fragility, fractures, vascular calcification, and increased cardiovascular mortality.

IMH manages CKD-MBD through a stage-based nephrology protocol, integrating biochemical monitoring and targeted therapy.

Management includes:

Strict phosphate control using dietary intervention and phosphate binders

Vitamin D replacement and active vitamin D analogues

Calcimimetic therapy for secondary hyperparathyroidism

Dialysis optimization in advanced CKD

Laboratory markers (calcium, phosphorus, PTH, alkaline phosphatase) are monitored regularly, and therapy is adjusted to avoid adynamic bone disease or hypercalcemia.

The goal is long-term skeletal integrity, cardiovascular risk reduction, and improved survival in CKD patients